Generated by AI
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases. The company’s work centers on gene regulation and epigenetic control, using its discovery platform to identify drug targets that may address the root causes of disease rather than only managing symptoms. Its lead clinical program, pociredir, is designed to increase fetal hemoglobin expression and is being studied for sickle cell disease. Fulcrum Therapeutics also advances research programs in other serious hematologic and rare disorders, including beta-thalassemia and inherited aplastic anemias, while maintaining a broader focus on areas of high unmet medical need. Based in Cambridge, Massachusetts, Fulcrum Therapeutics plays a specialized role in the biotechnology market as a developer of precision medicines for challenging diseases with limited treatment options.
Website26 Landsdowne Street
Cambridge, MA, 02139
United States
The latest articles about FULC.
Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.
Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.
Summary of Aug 17's posts. Generated by AI.
Summary of Dec 30's posts. Generated by AI.
Summary of Aug 17's posts. Generated by AI.
Investors talking about FULC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.